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Background. Although the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) system has become a prime target for
antiangiogenic treatment, its biological role in glioblastoma beyond angiogenesis has remained controversial.
Methods. Using neutralizing antibodies to VEGF or placental growth factor (PlGF) or the tyrosine kinase inhibitor, cediranib, or
lentiviral gene silencing, we delineated autocrine signaling in glioma cell lines. The in vivo effects of VEGFR1 and VEGFR2 depletion
were evaluated in orthotopic glioma xenograft models.
Results. VEGFR1 and VEGFR2 modulated glioma cell clonogenicity, viability, and invasiveness in vitro in an autocrine, cell– line-
specific manner. VEGFR1 silencing promoted mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)
signaling, whereas VEGFR2 silencing resulted in cell-type dependent activation of the protein kinase B (PKB)/AKT and MAPK/ERK
pathways. These responses may represent specific escape mechanisms from VEGFR inhibition. The survival of orthotopic glioma-
bearing mice was prolonged upon VEGFR1 silencing in the LNT-229, LN-308, and U87MG models and upon VEGFR2 silencing in
LN-308 and U87MG. Disruption of VEGFR1 and VEGFR2 signaling was associated with decreased tumor size, increased tumor
necrosis, or loss of matrix metalloproteinase 9 (MMP9) immunoreactivity. Neutralizing VEGF and PlGF by specific antibodies was
superior to either antibody treatment alone in the VEGFR1-dependent LNT-229 model.
Conclusions. Differential dependence on autocrine signaling through VEGFR1 and VEGFR2 suggests a need for biomarker–
stratified VEGF(R)-based therapeutic approaches to glioblastoma.
Keywords: angiogenesis, glioblastoma, PlGF, signaling, VEGF.
Glioblastoma, the most common intrinsic brain tumor, is
thought to originate from neuroglial progenitor cells. Glioblas-
toma cells are a rich source of angiogenic factors, notably vas-
cular endothelial growth factor (VEGF),1,2 and placental growth
factor (PlGF).3,4 Endothelial cells have been considered the
major target of glioblastoma-derived proangiogenic messen-
gers promoting tumor vascularization. In contrast, autocrine
or paracrine effects, defined as cross-talk among tumor cell
populations, have received little attention in glioblastoma.5 – 8
In mammals, VEGF signaling is a complex process involving
various receptor molecules. The VEGFR1 (FLT1) tyrosine kinase re-
ceptor (TKR) mediates various biologic effects of VEGFA, B, and
PlGF. VEGF or PlGF binding to VEGFR1 induces phosphorylation
and activation of extracellular signal-regulated kinases 1 and 2
(ERK1/2) and p38 mitogen-activated protein kinase (MAPK);
moreover, PlGF may stimulate the trans-phosphorylation of
specific VEGFR2 tyrosine residues.9,10 Specifically, VEGF and
PlGF expression by glioma cells may induce the accumulation
of VEGFR1–positive bone marrow-derived myeloid cells in
tumor tissue.7
Although VEGFR2 (KDR, FLK1) is considered the major
mediator of VEGFA, C, and D bioactivity in both physiologic and
pathologic angiogenesis, the mechanism of VEGF-induced phos-
phorylation of different tyrosine residues on VEGFR2 and the
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establishment of specific biological responses remain incom-
pletely understood. In addition, VEGFR heterodimerization and
interactions of VEGFR with coreceptors such as neuropilins
(NRP), heparan sulfate proteoglycans or avb3 integrin further
expand the complexity of signaling pathways activated by
VEGF and PlGF homo- or heterodimers.11 – 14 Finally, VEGFC/D
binding to VEGFR3 (FLT4) TKR is required for lymphangiogenesis
and may play a role in developmental and tumor angiogenesis
by modulating VEGFR2-mediated signals.15
Although VEGF receptors, NRP, integrins, and their ligands
are expressed in several tumor cell types,6,8,16 – 18 it is unclear
how distinct biological responses emanate from these recep-
tors, specifically in glioblastoma. Autocrine VEGF effects medi-
ated by VEGFR2 signaling have been proposed to promote
glioblastoma cell invasion, viability, and tumor growth.6,19
In contrast, VEGF binding to VEGFR2 has also been reported
to inhibit invasiveness by suppressing hepatocyte growth
factor-dependent c-MET activity through recruitment of the
phosphatase protein tyrosine phosphatase 1B (PTP1B) to the
VEGFR2/MET heterocomplex.20
These overall conflicting data on autocrine VEGFR signaling
led us to propose that responses to VEGFR pathway stimulation
or inhibition in glioma are heterogeneous and may, among
others, depend on the differential expression of VEGF family
ligands and receptors. In fact, we report here that VEGFR1 or
VEGFR2 signaling may exhibit distinct survival properties in
human glioma models in vivo and that a thorough characteri-
zation of VEGFR signaling in tumor cells may facilitate patient
enrichment for more successful clinical trials exploring
VEGF(R) inhibition in the future.
Materials and Methods
In Vitro Studies
Detailed information on reagents, cell lines, cell culture, viabil-
ity, clonogenicity, and spherogenicity assays is summarized in
Supplementary material, Note 1. Details on real-time quantita-
tive reverse transcription-PCR (qRT-PCR) and primers are provid-
ed with Supplementary material, Table S1, and details on
immunoblotting, flow cytometry, and ELISA are provided in
Supplementary material, Note 2.
The nonsilencing control (#RHS4348) and the silencing
microRNA-adapted shRNA (shRNAmir) pGIPZ lentiviral vectors
(#RHS4531-V3LHS_403557; #RHS4531-V3LHS_302174) con-
taining a single VEGFA (TCTGTATCGATCGTTCTGT) or VEGFR1-
targeting hairpin sequence (TGAACCTGAACTAGATCCT) provided
in bacterial stocks of E. coli were purchased from Thermo Scien-
tific Open Biosystems. Lentiviral infectious particles were pro-
duced in HEK 293T cells using pGIPZ shRNAmir lentiviral vector,
pCMV-dR8.91 second-generation packaging, and pMD2.G enve-
lope plasmids. To generate stable VEGFR2 gene-silenced cells,
glioma cells were transduced with VEGFR2-silencing shRNA
lentiviral particles (# sc-29318-V, Santa Cruz Biotechnology) con-
taining 3 target-specific constructs: ACTGTGGTGATTCCATGTCTT
CAAGAGAGACATGGAATCACCACAGTTTTTT; ACTTGTAAACCGAGA
CCTATTCAAGAGATAGGTCTCGGTTTACAAGTTTTTT; and CACCTGTTT
GCAAGAACTTTTCAAGAGAAAGTTCTTGCAAACAGGTGTTTTT. BLAST
analysis showed that the VEGFR1 targeting sequence (TGAA
CCTGAACTAGATCCT) may target the HRNR (Hornerin) gene (ex-
pect value (E) of 11); therefore, we performed a quantitative
PCR analysis to exclude this possibility in VEGFR1-silenced cells
(data not shown).
Nonsilencing shRNA virus was used as a negative control
(#sc-108080). In all cases, stable transduced clones were
selected with 4 mg/mL puromycin and used for analysis and
assays after 1–2 passages post selection. A pool of 3 target-
specific PlGF siRNA and control siRNA was purchased from
Santa Cruz and transfected with TransIT-X2 Dynamic Delivery
system (Mirus Bio LLC).
The invasive potential of glioma cells was measured by
spheroid invasion assay. Glioma spheroids were generated
from the respective cell lines by seeding 1 –5×103 cells in
100 mL of media onto 96-well plate base-coated with 1%
nobel agar/PBS medium substrate. After 2–3 days in culture,
spheroids with a mean diameter of 200 mm were transferred
to collagen I matrix-coated wells and covered by complete Dul-
becco’s modified Eagle’s medium. Every 24 hours for 3 days,
the pixel area covered by cells sprouting from these spheroids
was determined after subtraction of the initial spheroid pixel
area at time zero. Image J software (NIH) was used to deter-
mine the invasion area.
Animal Studies
The effects of antiangiogenic treatments or VEGFR depletion on
tumor growth and the survival of glioma-bearing mice were
examined in immunodeficient Crl:CD1-Foxn1nu nude mice
(Charles River). Mice were xenografted with 75 000 LNT-229 or
100 000 LN-308 or U87MG cells. Cells were stereotactically
implanted into the right striatum of 6- to 12-week-old mice.
Neurological symptoms were assessed daily according to the
Cantonal Veterinary Office Zurich guidelines (grade 0: no visible
impairment; grade 1: reduced activity, slight balance and coordi-
nation impairments; grade 2: reduced activity, 15% weight loss
compared with peak weight, slight paralysis of left legs, moder-
ate signs of pain). Seven animals were used to assess survival,
defined as the timepoint of the onset of symptoms (grade 2).
Data are presented as the number of surviving mice over the
time. For histology, 3 prerandomized animals per group were
euthanized when the first animal became symptomatic.
Animal experiments were conducted under valid licence and
permission of the Cantonal Veterinary Office Zurich and Federal
Food Safety and Veterinary Office. Mice were anesthetized by
intraperitoneal injection of fentanyl (Sintetica SA, )/midazolam
(Roche Pharma)/medetomidine (Orion Pharma mixture and
combined with analgesia using carprofen (Pfizer AG). Details
on histology and immunohistochemistry are provided in Sup-
plementary material, Note 3.
Statistical Analyses
Detailed information on statistical analysis is summarized in
Supplementary material, Note 4.
Results
Glioma Cell Lines Show Different Levels of Constitutive
and Inducible VEGFR1 and VEGFR2 Phosphorylation
To select appropriate models, we first screened our glioma cell
line panel for the expression of VEGF and PlGF and their recep-
tors at the mRNA and protein levels (Supplementary material,
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Notes 5 and 6; Supplementary material, Fig. S1–S6). Compared
with long-term cell (LTC) lines, glioma-initiating cell lines (GIC)
expressed lower levels of PlGF mRNA but were more responsive
to hypoxia with regard to VEGF release (Supplementary mate-
rial, Fig. S1D, F and G). Most cell lines exhibited VEGFR1 protein
on the cell surface (Supplementary material, Fig. S2C), whereas
VEGFR2 was not detected on the surface by flow cytometry
(Supplementary material, Fig. S2D). However, immunoblot
(Fig. 1A and B) and intracellular flow cytometry (Supplementary
material, Fig. S2E and F) revealed significant intracellular levels
of both receptors. Immunoblot showed the highest VEGFR2
protein levels in U87MG, LN-308, and T-325 (Fig. 1B). Total
protein levels did not correlate to phosphorylation of the
major tyrosine site, VEGFR1Tyr1213 or VEGFR2Tyr1059 (Fig. 1A
and B) or the total levels of p-VEGFR1 or p-VEGFR2 measured
by capture ELISA (Fig. 1C and D), suggesting multiple effects
of interacting mechanisms triggered by various ligands.
Next, we studied the phosphorylation status of VEGFR1
and VEGFR2 (total p-VEGFR) at baseline and after stimulation
with recombinant VEGF. p-VEGFR1 was induced by VEGF only
in LN-308 and p-VEGFR2 only in human umbilical vein endo-
thelial cells (HUVEC) (Fig. 1C and D). The specificity of the
ELISA was supported by stimulation of HUVEC with VEGF
and the reduction by cediranib in LN-308. Incomplete
correlation between Figs. 1A–D is likely a result of comparing
single versus all phosphorylated residues of VEGFR.
Constitutive VEGFR1 and VEGFR2 phosphorylation was sen-
sitive to the pan-VEGFR inhibitor, cediranib, in ZH-161 cells with
Fig. 1. Autocrine and induced vascular endothelial growth factor receptor (VEGFR) activation in glioma cells. (A, B) The levels of total VEGFR1 and
VEGFR2 as well as of phosphorylated VEGFR1Tyr1213 or VEGFR2Tyr1059 were assessed by immunoblot, using actin as a loading control. (C, D)
Constitutive and VEGF-evoked total phosphorylation levels of VEGFR1 or VEGFR2 were determined by ELISA (*P, .05). (E) VEGFR1 and VEGFR2
phosphorylation in response to increasing concentrations of cediranib (2 h) in ZH-161 cells were detected by immunoblot. (F) Effects of VEGF or
PlGF stimulation or neutralizing anti-VEGF (B20) or anti-placental growth factor (PlGF) (TB403) antibodies on VEGFR1Tyr1213 in LNT-229 cells were
assessed by immunoblot; cells were incubated for 15 minutes with VEGF (500 ng/mL) or PlGF(1+ 2) (200 ng/mL) alone or in combination with
neutralizing VEGF or PlGF antibodies (100 mg/mL). (G) Effects of lentivirus-mediated VEGFA shRNAmir (left) or PlGF siRNA (right) on constitutive
p-VEGFR1Tyr1213 in U87MG or LNT-229 cells, respectively, were evaluated by immunoblot.
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IC50 values of0.3 mM (Fig. 1E), indicating autocrine activation.
Sensitivity to cediranib thus confirmed the specificity of the 2
main bands detected by immunoblot. p-VEGFR2 was less sen-
sitive to cediranib than p-VEGFR1.
To separate constitutive versus inducible VEGFR1 phosphor-
ylation at Tyr1213, LNT-229 cells were unstimulated or exposed
to ligand for 15 minutes after 12 hours of serum starvation and
washing. The cells were preincubated for 2 hours in serum-free
condition with neutralizing antibodies to VEGF (B20) or PlGF
(TB403) before stimulation with VEGF or PlGF. Exogenous
VEGF and PlGF stimulated VEGFR1Tyr1213 phosphorylation in
LNT-229. B20 or TB403 interfered only with exogenous VEGF-
or PlGF-induced p-VEGFR1Tyr1213 (Fig. 1F). In contrast, constitu-
tive p-VEGFR1Tyr1213 was reduced in response to PlGF or VEGFA
gene silencing in U87MG or LNT-229 cells, respectively (Fig. 1G;
Supplementary material, Fig. S7A and B), confirming their auto-
crine activity.
Not surprisingly, we determined that higher VEGFR1 or VEGFR2
mRNA expression levels were associated with higher tumor grade
and worse prognosis (Supplementary material, Fig. S8).
VEGFR1 and VEGFR2 Gene Silencing Affect Major
Signaling Pathways in Glioma Cells
Untreated or ligand-stimulated control or VEGFR-depleted cells
were analyzed by immunoblot to gain insight into the molecu-
lar changes triggered by VEGFR gene silencing. To test VEGF sig-
naling, we used recombinant VEGF112 (Ala207 - Arg318).
21 Both
VEGF and PlGF induced phosphorylation of p44/42 (ERK1/2) and
p38 MAPK in LNT-229 and LN-308 (Fig. 2A). In contrast, p-AKT
levels were largely unaffected. VEGFR1 gene silencing alone re-
sulted in an increase of p44/42 (ERK1/2) phosphorylation com-
pared with the control cells in both models, and this stimulation
was not superinduced by exogenous VEGF or PlGF. Phospho-p38
MAPK increased in VEGFR1-depleted LN-308. VEGFR1 gene
silencing attenuated the VEGF or PlGF-induced stimulation
of p38 MAPK to a different extent, raising the possibility of
VEGFR1-dependent signaling of VEGF and PlGF to p38 MAPK.
VEGFR2 gene silencing increased p-VEGFR2Tyr1175 in ZH-161,
p-AKTThr308, and p-p44/42 (ERK1/2)Thr202/Tyr204 in LN-308
and LN-428 and phospho-p38 MAPK in LN-308 and ZH-161.
Yet, when VEGFR2 expression was silenced, p-p44/42 (ERK1/2)
and p-p38 MAPK were no longer induced by VEGF in LN-308
(Fig. 2B).
VEGFR1 and VEGFR2 Signaling in Glioma Cells Modulates
Clonogenic Survival and Invasion in a Cell–
line-dependent Manner
The role of VEGFR signaling in glioblastoma cells was studied
pharmacologically and genetically. Clonogenic survival was as-
sessed by crystal violet staining for LTC or by spherogenicity for
GIC. B20 and TB403 alone or in combination at 100 mg/mL had
no effect in these assays in LNT-229 or ZH-161. Similarly, there
was no effect of exogenous VEGF or PlGF. In contrast, cediranib
reduced clonogenicity of LNT-229 and spherogenicity of
ZH-161 with an EC50 of 3 mM. These concentrations had no
significant effect on viability (Supplementary material,
Fig. S9A and B, data not shown). For VEGFR1 gene silencing,
we selected 4 cell lines (3 LTC (LNT-229, LN-308, and U87MG)
and one GIC (ZH-161)), all possessing high VEGFR1 expression.
Two LTC (LN-308, U87MG) and one GIC (T-325) with high VEGFR2
expression and further cell lines with lower VEGFR2 expression
(LN-428, LNT-229, and ZH-161) were selected for VEGFR2 gene
silencing. Successful gene silencing of VEGFR1 was confirmed by
qRT- PCR (Supplementary material, Fig. S7C, E, G and K),
Fig. 2. Altered downstream signaling in vascular endothelial growth factor receptor (VEGFR)1- and VEGFR2-depleted glioma cells. (A) Stably
VEGFR1 gene-silenced LNT-229 or LN-308 cells or (B) VEGFR2 gene-silenced LN-308, LN-428, ZH-161 or T-325 cells, or corresponding controls
were assayed for changes in downstream signaling by immunoblot. After 12 hours of serum starvation, subconfluent cells were untreated or
stimulated with VEGF (500 ng/mL) or placental growth factor (PlGF) (1+ 2) (100+ 100 ng/mL) as indicated for 15 minutes.
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
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immunoblot (Fig. 2A; Supplementary material, Fig. S10A), flow
cytometry (Supplementary material, Fig. S2E), and total
p-VEGFR1 ELISA (data not shown). VEGFR2 gene silencing was
verified by qRT-PCR (Supplementary material, Fig. S7D, F, H, I, J,
and L), immunoblot (Fig. 2B, Supplementary material, Fig. S10A),
flow cytometry (Supplementary material, Fig. S2F) and total
p-VEGFR2 ELISA (data not shown). Flow cytometry revealed a
minor induction of apoptosis upon VEGFR1 depletion in LN-308
but not LNT-229. VEGFR2 depletion had no such effect in LN-308
but increased the G2/M fraction (Supplementary material,
Fig. S9C, D and E). Accordingly, VEGFR1/2 depletion did not affect
the doubling time of LNT-229 (25–30 h), where depletion of ei-
ther receptor prolonged doubling times from 40–50 hours in
LN-308 (data not shown). Further, VEGFR1 gene silencing de-
creased clonogenicity to 67% in LNT-229 and 14% in LN-308
and spherogenicity to 7% in ZH-161 (Fig. 3A). Similarly, VEGFR2
Fig. 3. Biological effects of vascular endothelial growth factor receptor (VEGFR) signaling inhibition in glioma cells. Effects of VEGFR1 gene silencing
on (A) clonogenicity or spherogenicity and (B, C) invasion of LNT-229 were studied. (D, E) Effects of VEGFR2 gene silencing on clonogenicity and
spherogenicity was evaluated. (F, G). Invasiveness of VEGFR2-depleted LN-308 cells was assessed by spheroid invasion assays. The data represent
the average fold change in area of 3 spheroids+standard deviation (*P, .05).
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
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gene silencing reduced clonogenicity of U87MG, LN-308, and
LN-428, although not in LNT-229, and spherogenicity in
ZH-161 and T-325 (Fig. 3D and E). The specificity of the knock-
down effects was confirmed by rescue experiments: clonogenic-
ity was restored by CMV promoter-driven exogenously
re-expressed VEGFR1 (P¼ .01) or VEGFR2 (P¼ .01) (Supplemen-
tary material, Fig. S10). At 72 hours VEGFR1 gene silencing inhib-
ited invasion by 29% (P¼ .03) in LNT-229 (Fig. 3B and C). The
invasiveness of the less invasive LN-308 cells was not suppressed
by VEGFR1 depletion. Conversely, VEGFR2 depletion reduced in-
vasiveness of LN-308 cells (Fig. 3F and G) to a similar extent as
cediranib, but there was no effect on LNT-229 (data not shown).
VEGFR1 and VEGFR2 Support Tumor Growth in Orthotopic
Rodent Glioma Models
Finally, we investigated whether genetic or pharmacologic
VEGFR inhibition affected tumor growth in vivo. Mice inoculated
with VEGFR1-silenced LNT-229 (P¼ .026), LN-308 (P¼ .042), or
U87MG (P¼ .003) cells experienced a significant survival bene-
fit (Fig. 4A and B; Supplementary Material, Fig. S11B). In the
LN-308 model, all control mice had to be euthanized because
of tumor growth, whereas 3 mice in the shVEGFR1mir group
were alive and free from major signs at day 190. Analysis of
brain sections of these 3 surviving mice showed that only one
Fig. 4. Genetic depletion of vascular endothelial growth factor receptor (VEGFR)1 or pharmaceutical neutralization of both VEGFR1 ligands, VEGF
and placental growth factor (PlGF), delay tumor growth in vivo. (A) 75 000 nontargeting control shRNAmir-expressing human LNT-229 glioma cells
were implanted into the brains of nude mice. The mice were treated either twice weekly with 20 mg/kg/day Xolair IgG control or 5 mg/kg/day B20
or 20 mg/kg/day TB403 by intraperitoneal injection. The treatment was initiated at the day of tumor implantation and maintained until the onset
of clinical grade 2 symptoms. A parallel group of mice was transplanted with 75 000 VEGFR1-targeted shRNA expressing LNT-229 glioma cells. (B)
100 000 VEGFR1-silenced or corresponding control LN-308 cells were implanted into the brains of nude mice. Seven animals per group were used
to monitor survival (Mantel-Cox test). (C) LNT-229 tumor specimens obtained per randomization list from animals sacrificed on the same day in
each group when the first animal(s) became symptomatic were stained for p-VEGFR1Tyr1213 (brown color). Sections were counterstained with
hematoxylin (blue). A higher magnification image shown in Fig. S12A confirmed subcellular localization. (D) LNT-229 tumor specimens or
normal brain were stained for MMP9 immunoreactivity (brown color). Sections were counterstained with hematoxylin (blue). (E) LNT-229
tumor sizes were assessed on H&E-stained sections (n¼ 3; *P, .05, t test).
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
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mouse harbored a small tumor of 0.12 mm2. Appropriate
control experiments confirmed that p-VEGFR1 levels were
strongly suppressed in the VEGFR1-silenced tumors at days
22 (LNT-229), 27 (U87MG) or 44 (LN-308) in all models
(Fig. 4C; Supplementary material, Fig. S11F and S12B). Further-
more, immunoreactivity of matrix metalloproteinase (MMP)
9 was strongly reduced in LNT-229 (Fig. 4D). A survival effect
similar to VEGFR1 silencing was afforded by treatment of
mice carrying LNT-229 control tumors with TB403 but not
B20 (Fig. 4A). The latter was in part due to early onset of
score 2 adverse events (≥15% weight loss) with B20 treatment.
All interventions reduced areas involved by tumor at day 22
(Fig. 4E).
To determine possible synergy by inhibiting both growth
factors, we allowed the tumors to establish for 15 days and
then initiated treatment with either VEGF or PlGF antibody or
both until progression. In this paradigm, compared with the
control group, only cotreatment afforded a survival advantage
(P¼ .009) (Fig. 5A). In control tumors, CD31 staining revealed a
prominent signal, particularly at the tumor edges, which was
associated with the invasion of glioma cells along the vessels.
Invasive cells at the tumor periphery, as well as glioma cells in
tumor satellites of control tumors, displayed strong p-VEGFR1
staining relative to the tumor core, indicating a role of
VEGFR1 in tumor cell invasion in vivo. All interventions resulted
in decreased p-VEGFR1 levels, decreased MMP9 immunoreac-
tivity, and a trend towards decreased vessel density deter-
mined by CD31 staining and (Fig. 5B and C).
VEGFR2 depletion delayed tumor growth profoundly in
LN-308 (P¼ .003) and U87MG (P¼ .009) but not in LNT-229
(Fig. 6A, B and E; Supplementary material, Fig. S11C and D),
although gene silencing was confirmed to persist in all models
(Fig. 6C and D; Supplementary material, Fig. S11F). Compared
with the controls, tumor sizes and MMP9 protein levels in the
tumor core and invasive area were strongly reduced by
VEGFR2 gene silencing in LN-308 (Fig. 6E and F).
Fig. 5. Synergistic growth inhibition by targeting both vascular endothelial growth factor receptor (VEGFR)1 ligands, VEGF and placental growth
factor (PlGF) in vivo. (A) A similar experiment as in Fig. 4A was performed, but with the modification that antibody treatment was delayed until day
15 after tumor implantation and that another group of animals treated with both VEGF and PlGF antibody were included. (B) Tumor specimens
obtained per randomization list from animals sacrificed on the same day in each group when the first animal(s) became symptomatic were stained
for p-VEGFR1Tyr1213 (upper row, brown color), CD31 (middle row) or MMP9 (lower row). Sections were counterstained with hematoxylin (blue). (C)
Quantification of immunoreactivity (n¼ 3; *P, .05, t test).
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
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Discussion
The standard of care for patients with newly diagnosed
glioblastoma includes resection or biopsy followed by radio-
therapy and concomitant maintenance temozolomide.22,23
Many contemporary efforts to improve on this standard have
explored the hypothesis that inhibition of angiogenesis will
provide a survival benefit. In 2 randomized phase 3 trials, the
most advanced antiangiogenic agent (ie, the VEGF antibody
bevacizumab) has shown activity defined by an increased
radiological response rate and prolonged progression-free
survival, although not overall survival.24,25 In contrast, other
VEGF-targeting agents such as cediranib or VEGF trap or
non-VEGF-targeting antiangiogenic agents such as enzastaurin
or cilengitide have failed.26 The search for and clinical validation
of biomarkers that help select patients deriving benefit from
antiangiogenic treatment continues.27,28
Of note, VEGF may also assume an angiogenesis-independent
tumor-promoting function.29,30 Despite interest in the auto-
crine effects of VEGF on tumor cells, and specifically glioma
cells,8,20 distinct biological functions and signaling pathways
mediated by different VEGF-receptors in glioma cells have not
been systemically analyzed. Here we have performed a com-
prehensive expression profiling of human glioma cells, including
GIC, for VEGF family ligands and receptors. Most glioma cells
coexpress various VEGF and PlGF species and their cognate
receptors, however, at different levels (Supplementary Notes
5 and 6).
Fig. 6. Genetic depletion of vascular endothelial growth factor receptor (VEGFR)2 delays tumor growth in the LN-308 but not in the LN-229 glioma
model. (A,B) 75 000 LNT-229 or 100 000 LN-308 depleted of VEGFR2 or their shRNA control cells were implanted intracranially and monitored for
survival (n¼ 7). (C, D) VEGFR2 gene silencing was confirmed by immunofluoresence microscopy at days 21 (LNT-229) or 37 (LN-308). Preservation
of blood vessel labeling after tumor-specific gene silencing serves as an internal control. (E) LN-308 tumor sizes were determined based on
H&E-stained sections (n¼ 3). (F) IHC for MMP9 levels upon VEGFR2 silencing. The mean area (a.u.) of MMP9-positive segments was reduced by
86% relative to control values (n¼ 3, P, .05).
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VEGFR1 expression was identified at the surface of almost all
glioma cell lines by flow cytometry. The presence of an intracel-
lular VEGFR1 pool was evidenced by the major shift of the flow
cytometry signal in the permeabilized LNT-229 and LN-308
cells (Supplementary material, Fig S2). Only LNT-229 and
LN-308 cells expressed soluble VEGFR1 (Supplementary mate-
rial, Fig. S6B). VEGFR2 internalization and intracellular signaling
have been described.31 VEGFR2 protein was only revealed by
immunoblot and flow cytometry of prepermeabilized cells but
not at the surface of nonpermeabilized cells, confirming intra-
cellular localization (Supplementary material, Fig. S2F).
Most glioma cells exhibited autocrine VEGFR1 phosphoryla-
tion that is only slightly inducible by recombinant VEGF (Fig. 1A,
C and F; Fig. 2A). VEGFR1 is phosphorylated at tyrosine Y1213 in
response to both VEGF and PlGF on immunoblots. In contrast to
cediranib, neutralizing antibodies to VEGF (B20) or PlGF (TB403)
did not inhibit constitutive Tyr1213 phosphorylation. Yet, stim-
ulation of VEGFR1Y1213 by recombinant VEGF or PlGF in LNT-229
was neutralized by B20 and less so by TB403, respectively
(Fig. 1E and F).
Phosphorylation of VEGFR2Tyr1059; Tyr1175, suggestive of auto-
crine signaling was also detected in some cell lines. Total
VEGFR2 phosphorylation was not inducible by exogenously
added VEGF in vitro, supporting the absence of VEGFR2 on
the cellular surface (Fig. 1B and D; Fig. 2B).
We confirm that exogenous VEGF or PlGF and anti-VEGF or
PlGF neutralizing antibodies have little or no effect on glioblas-
toma cell growth in vitro32 (Supplementary material, Fig. S9A
and B). Ligand interaction with VEGFR1 and VEGFR2 may be
sterically protected from antibody interference but still target-
ed by intracellularly acting agents such as cediranib (Fig. 1E
and F). Accordingly, VEGFA- or PlGF-deficient glioma cells had
reduced basal p-VEGFR1Tyr1213, confirming endogenous ligand-
dependent receptor phosphorylation (Fig. 1G).
To better delineate autocrine signaling and deduce the
biological role of VEGF family receptors, cell lines with different
levels of VEGFR1 or VEGFR2 expression and activation were sub-
jected to receptor-specific gene silencing by lentivirus-delivered
shRNA. VEGFR2 gene silencing had major effects in cell lines
with increased intracellular VEGFR2 levels lacking detectable
VEGFR2 at the cell surface and indicating that autocrine
VEGFR2 signaling is regulated at the level of cytoplasmic intra-
cellular receptor cycling. Silencing of either receptor resulted
in distinct changes in downstream signaling that may be inter-
preted as a stress response and point to potential escape strat-
egies that might be exploited therapeutically: phosphorylation
of MAPK in response to VEGFR1 depletion and of AKT and MAPK
in response to VEGFR2 depletion (Fig. 2).
VEGFR-depleted glioma cells showed a strong phenotype at
the level of clonogenicity, spherogenicity, and invasiveness in a
cell line- and receptor type-dependent manner (Fig. 3). For
example, clonogenic growth and invasion of LNT-229 cells
were unaffected by VEGFR2 depletion, consistent with low-level
VEGFR2 expression and phosphorylation, whereas VEGFR1
depletion led to a significant decrease of both clonogenic and
motogenic potential demonstrating that VEGFR2 signaling is
dispensable in some glioma cell lines. In contrast, the clono-
genic survival of VEGFR1 and VEGFR2 high-expressing LN-308
cells was strongly affected by the silencing of both receptors.
Unlike LNT-229, downregulation of VEGFR2 significantly
inhibited invasion, whereas VEGFR1 gene silencing hardly af-
fected invasion in LN-308. Rescue experiments further con-
firmed the specific biological functions of both receptors
(Supplementary material, Fig. S10).
These observations were expanded and confirmed by in vivo
studies in nude mice. VEGFR1 phosphorylation was unevenly
distributed throughout LNT-229 tumors with predominant
staining localized to the infiltrating tumor edge. Either
shRNAmir-mediated suppression of VEGFR1 or the early expo-
sure of mice to neutralizing antibodies to VEGF or PlGF inhibited
VEGFR1 phosphorylation and reduced tumor growth (Fig. 4A).
Using a paradigm of pre-established tumors, the combination
of both antibodies was superior to administration of either
antibody alone and conferred a significant survival benefit in
the LNT-229 model (Fig. 5A). The inhibition of VEGFR1 expression
or activity was uniformly associated with loss of MMP9 levels in
the tumors. Among various MMP, only the transcriptional and
enzymatic levels of MMP9 correlated with tumor grade in glio-
mas.33 Correlation analyses using gene expression data from
TCGA-540 database (http://hgserver1.amc.nl/cgi-bin/r2/main.
cgi#) confirmed that MMP9 expression correlated with VEGFR1
expression (r¼ 0.26, 8e-10) and VEGFR2 expression (r¼ 0.22,
P¼ 1.4e-7) (data not shown).
A role for VEGFR1 signaling in tumor cells in promoting
tumor growth has been reported in different tumor mod-
els,3,29,34 – 36 however, not yet in glioblastoma. Although the
addition of TB403 to bevacizumab did not generate a signal
of enhanced activity in a phase 1 study in human patients
with recurrent glioblastoma,37 the patient number was small,
and no effort was made to preselect patients based on
VEGFR1 phosphorylation. Thus, a biomarker-driven clinical
trial focusing on p-VEGFR1 levels and PlGF expression in glio-
blastoma might still represent an effective strategy to define
a role for PlGF targeting in glioblastoma or other cancers. Sim-
ilarly, one might speculate that an enrichment of glioblastomas
dependent on VEGFR signaling might have helped to define a
role for cediranib in subsets of glioblastoma patients.38 VEGFR2
gene silencing resulted in profound growth inhibition associated
with reduced MMP9 immunoreactivity in the LN-308 model,
further delineating an important tumor-promoting function
of VEGFR2 in selected gliomas (Fig. 6). The potential role of
VEGFR1/2 in tumor growth was confirmed in the U87MG
model (Supplementary material, Fig. S11).
Altogether, this systematic analysis of VEGF receptors using
different glioma models indicates differential biologic functions
of VEGFR1 and VEGFR2 that may be context-dependent. Such
in-depth studies may also resolve some apparently contradic-
tory research findings (eg, PlGF has been shown to promote
tumor growth and local invasiveness in subcutaneous melano-
ma, orthotopic pancreatic syngeneic tumors and GL-261 ro-
dent glioma models,7,39 or to inhibit tumor growth in lung,
colon, and U87MG glioma models).40 Similarly, VEGFR2 has
been reported to promote glioma cell viability and inva-
sion;6,8,19 however, blocking VEGFR2 may also trigger invasive-
ness of some glioma cells by activating the c-MET pathway.20
Although VEGF antagonism has been shown to limit glioma
growth in rodent models in vivo,41 this effect has commonly
been attributed to antiangiogenesis. We now provide firm evi-
dence that intrinsic VEGFR signaling in glioma cells sustains gli-
oma growth at least in certain models: VEGFR1 suppression
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
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induced a major delay of tumor growth in the LNT-229, LN-308,
and U87MG models (Fig. 4 and 5; Supplementary material,
Fig. S11 and S12), whereas VEGFR2 decreased growth in
LN-308 and U87MG (Fig. 6; Supplementary material, Fig. S11).
Translating VEGFR expression into a prognostic or predictive
biomarker may remain challenging and require careful consid-
eration of the type and level of intratumoral VEGFR phosphory-
lation, tumoral versus endothelial expression, intratumoral
heterogeneity, alternatively spliced VEGFR variants, and solu-
ble, proteolytically cleaved, truncated VEGFR1 and VEGFR2
variants.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal
online (http://neuro-oncology.oxfordjournals.org/).
Funding
Swiss National Science Foundation (SNF) (to M.W.).
Acknowledgments
The authors would like to express their sincere appreciation to Konrad
Honold (Roche Innovation Center Penzberg, Pharma Research and Early
Development) for his support. The authors thank Silvia Dolski and Julia
Friesen for expert technical assistance.
Conflict of interest statement. E.S. was a recipient of a Postdoctoral
Fellowship from Roche (Basel, Switzerland). H.S. and E.R. report no
conflicts of interest. K.S. has received honoraria for advisory board
participation from Roche. F.H. and K.M.W. are employed by Roche.
M.W. has received research grants from Acceleron, Actelion, Alpinia
Institute, Bayer, Isarna, M.S.D., Merck & Co, Novocure, PIQUR and
Roche and honoraria for lectures or advisory board participation or
consulting from Celldex, Immunocellular Therapeutics, Isarna,
Magforce, M.S.D., Merck & Co, Northwest Biotherapeutics, Novocure,
Pfizer, Roche, and Teva.
References
1. Folkins C, Shked Y, Man S, et al. Glioma tumor stem-like cells
promote tumor angiogenesis and vasculogenesis via vascular
endothelial growth factor and stromal-derived factor 1. Cancer
Res. 2009;69(18):7243–7251.
2. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth-factor
and glioma angiogenesis - coordinate induction of VEGF receptors,
distribution of VEGF protein and possible in-vivo regulatory
mechanisms. Int J Cancer. 1994;59(4):520–529.
3. Yao J, Wu XM, Zhuang GL, et al. Expression of a functional VEGFR-1
in tumor cells is a major determinant of anti-PlGF antibodies
efficacy. Proc Natl Acad Sci U S A. 2011;108(28):11590–11595.
4. Nomura M, Yamagishi S, Harada S, et al. Placenta growth factor
(PlGF) mRNA expression in brain tumors. J Neurooncol. 1998;
40(2):123–130.
5. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular
endothelial growth factor and placental growth factor contributes
to angiogenesis and plasma extravasation in pathological
conditions. Nat Med. 2001;7(5):575–583.
6. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine
VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-
like cell viability and tumor growth. J Exp Med. 2012;209(3):
507–520.
7. Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in
macrophages promotes glioma growth in vivo. Cancer Res. 2008;
68(18):7342–7351.
8. Knizetova P, Ehrmann J, Hlobilkova A, et al. Autocrine regulation of
glioblastoma cell cycle progression, viability and radioresistance
through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle. 2008;7(16):
2553–2561.
9. Autiero M, Waltenberger J, Communi D, et al. Role of PIGF in the
intra- and intermolecular cross talk between the VEGF receptors
Flt1 and Flk1. Nat Med. 2003;9(7):936–943.
10. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of
VEGFR-1 signal transduction pathways in primary human
monocytes. Arterioscl Throm Vas. 2008;28(2):322–328.
11. Cao YH, Chen H, Zhou L, et al. Heterodimers of placenta growth
factor vascular endothelial growth factor - Endothelial activity,
tumor cell expression, and high affinity binding to Flk-1/KDR.
J Biol Chem. 1996;271(6):3154–3162.
12. Cudmore MJ, Hewett PW, Ahmad S, et al. The role of
heterodimerization between VEGFR-1 and VEGFR-2 in the
regulation of endothelial cell homeostasis. Nat Commun. 2012;
3:1–12.
13. Dixelius J, Makinen T, Wirzenius M, et al. Ligand-induced vascular
endothelial growth factor receptor-3 (VEGFR-3) heterodimerization
with VEGFR-2 in primary lymphatic endothelial cells regulates
tyrosine phosphorylation sites. J Biol Chem. 2003;278(42):
40973–40979.
14. Favier B, Alam A, Barron P, et al. Neuropilin-2 interacts with
VEGFR-2 and VEGFR-3 and promotes human endothelial cell
survival and migration. Blood. 2006;108(4):1243–1250.
15. Zhang LQ, Zhou F, Han WC, et al. VEGFR-3 ligand-binding and
kinase activity are required for lymphangiogenesis but not for
angiogenesis. Cell Res. 2010;20(12):1319–1331.
16. Gee MFW, Tsuchida R, Eichler-Jonsson C, et al. Vascular
endothelial growth factor acts in an autocrine manner in
rhabdomyosarcoma cell lines and can be inhibited with
all-trans-retinoic acid. Oncogene. 2005;24(54):8025–8037.
17. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by
endothelial and tumor cells as an isoform-specific receptor for
vascular endothelial growth factor. Cell. 1998;92(6):735–745.
18. Tanno S, Ohsaki Y, Nakanishi K, et al. Human small cell lung cancer
cells express functional VEGF receptors, VEGFR-2 and VEGFR-3.
Lung Cancer. 2004;46(1):11–19.
19. Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF
enhances glioma cell motility in vitro. Radiat Oncol. 2012;7:1–9.
20. Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell
invasion and mesenchymal transition through a MET/VEGFR2
complex. Cancer Cell. 2012;22(1):21–35.
21. Pan Q, Chathery Y, Wu Y, et al. Neuropilin-1 binds to VEGF(121) and
regulates endothelial cell migration and sprouting. J Biol Chem.
2007;282(33):24049–24056.
22. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. New
Engl J Med. 2005;352(10):987–996.
23. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the
diagnosis and treatment of anaplastic gliomas and glioblastoma.
Lancet Oncol. 2014;15(9):E395–E403.
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
10 of 11 Neuro-Oncology
 at U
niversitaet Zuerich on A
pril 26, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
24. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus
radiotherapy-temozolomide for newly diagnosed glioblastoma.
New Engl J Med. 2014;370(8):709–722.
25. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of
bevacizumab for newly diagnosed glioblastoma. New Engl J Med.
2014;370(8):699–708.
26. Batchelor TT, Reardon DA, de Groot JF, et al. Antiangiogenic
therapy for glioblastoma: current status and future prospects.
Clin Cancer Res. 2014;20(22):5612–5619.
27. Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural
glioblastoma may derive overall survival benefit from the
addition of bevacizumab to first-line radiotherapy and
temozolomide: retrospective analysis of the AVAglio trial. J Clin
Oncol. 2015;33(25):2735–U2737.
28. Tabouret E, Boudouresque F, Farina P, et al. MMP2 and MMP9 as
candidate biomarkers to monitor bevacizumab therapy in
high-grade glioma. Neuro Oncol. 2015;17(8):1174–1176.
29. Lee TH, Seng S, Sekine M, et al. Vascular endothelial growth factor
mediates intracrine survival in human breast carcinoma cells
through internally expressed VEGFR1/FLT1. Plos Med. 2007;4(6):
1101–1116.
30. Cao Y, E GQ, Wang EF, et al. VEGF exerts an angiogenesis-
independent function in cancer cells to promote their malignant
progression. Cancer Res. 2012;72(16):3912–3918.
31. Lampugnani MG, Orsenigo F, Gagliani MC, et al. Vascular
endothelial cadherin controls VEGFR-2 internalization and
signaling from intracellular compartments. J Cell Biol. 2006;
174(4):593–604.
32. Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit
angiogenesis during primary tumor growth. Cell. 2010;141(1):
166–177.
33. Forsyth PA, Wong H, Laing TD, et al. Gelatinase-A
(MMP-2), gelatinase-B (MMP-9) and membrane type matrix
metalloproteinase-1 (MT1-MMP) are involved in different aspects
of the pathophysiology of malignant gliomas. Brit J Cancer. 1999;
79(11–12):1828–1835.
34. Frank NY, Schatton T, Kim S, et al. VEGFR-1 expressed by malignant
melanoma-initiating cells is required for tumor growth. Cancer
Res. 2011;71(4):1474–1485.
35. Lesslie DP, Summy JM, Parikh NU, et al. Vascular endothelial
growth factor receptor-1 mediates migration of human
colorectal carcinoma cells by activation of Src family kinases.
Brit J Cancer. 2006;94(11):1710–1717.
36. Mezquita B, Mezquita P, Pau M, et al. Unlocking doors without keys:
activation of Src by truncated C-terminal intracellular receptor
tyrosine kinases lacking tyrosine kinase activity. Cells. 2014;3(1):
92–111.
37. Lassen U, Chinot OL, McBain C, et al. Phase 1 dose-escalation
study of the antiplacental growth factor monoclonal antibody
RO5323441 combined with bevacizumab in patients with
recurrent glioblastoma. Neuro Oncol. 2015;17(7):1007-15.
38. Batchelor TT, Mulholland P, Neyns B, et al. III randomized trial
comparing the efficacy of cediranib as monotherapy, and in
combination with lomustine, versus lomustine alone in patients
with recurrent glioblastoma. J Clin Oncol. 2013;31(26):
3212–3218.
39. Fischer C, Jonckx B, Mazzone M, et al. Anti-PIGF inhibits growth of
VEGF(R)-inhibitor-resistant tumors without affecting healthy
vessels. Cell. 2007;131(3):463–475.
40. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor
overexpression inhibits tumor growth, angiogenesis, and
metastasis by depleting vascular endothelial growth factor
homodimers in orthotopic mouse models. Cancer Res. 2006;
66(8):3971–3977.
41. Cheng SY, Huang HJS, Nagane M, et al. Suppression of
glioblastoma angiogenicity and tumorigenicity by inhibition of
endogenous expression of vascular endothelial growth factor.
Proc Natl Acad Sci U S A. 1996;93(16):8502–8507.
Szabo et al.: Autocrine VEGF receptor signaling in glioblastoma
Neuro-Oncology 11 of 11
 at U
niversitaet Zuerich on A
pril 26, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
